Core Alternative Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Core Alternative Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.1K	Hold	123	–	–	0.02%	145
2026 Q1	$54.9K	Hold	123	–	–	0.02%	141
2025 Q4	$55.8K	Sell	123 -8	-6%	-$3.45K	0.02%	142
2025 Q3	$51.3K	Hold	131	–	–	0.01%	124
2025 Q2	$58.3K	Hold	131	–	–	0.02%	119
2025 Q1	$63.5K	Hold	131	–	–	0.02%	123
2024 Q4	$52.8K	Hold	131	–	–	0.01%	142
2024 Q3	$60.9K	Hold	131	–	–	0.01%	139
2024 Q2	$61.4K	Hold	131	–	–	0.01%	137
2024 Q1	$54.8K	Buy	131 +49	+60%	+$20.7K	0.01%	141
2023 Q4	$33.4K	Sell	82 -109	-57%	-$40.3K	0.01%	189
2023 Q3	$66.4K	Buy	191 +105	+122%	+$36.7K	0.01%	167
2023 Q2	$30.3K	Sell	86 -31	-26%	-$10.4K	﹤0.01%	188
2023 Q1	$36.9K	Buy	117 +43	+58%	+$12.9K	﹤0.01%	177
2022 Q4	$21.4K	Hold	74	–	–	﹤0.01%	211
2022 Q3	$21K	Hold	74	–	–	﹤0.01%	218
2022 Q2	$21K	Buy	74 +26	+54%	+$6.96K	0.01%	218
2022 Q1	$13K	Buy	48 +26	+118%	+$6.17K	﹤0.01%	243
2021 Q4	$5K	Buy	+22	New	+$4.28K	﹤0.01%	195

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Core Alternative Capital's VRTX Position: Q2 2026 in Review

Core Alternative Capital held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 123 shares worth $61.1K. The position accounts for 0.02% of the portfolio, ranked #145.

Core Alternative Capital first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $66.4K in Q3 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Core Alternative Capital held 123 shares of Vertex Pharmaceuticals worth $61.1K as of Q2 2026.
Core Alternative Capital left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of Core Alternative Capital's portfolio in Q2 2026, its #145 holding.
Core Alternative Capital first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Core Alternative Capital's Vertex Pharmaceuticals position peaked at $66.4K in Q3 2023.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Core Alternative Capital's 13F filing for Q2 2026, filed 14 Aug 2026.